Combining molecular data and clinical annotation of tumor cohorts, now available in a public, but increasingly also in a clinical context has the potential to greatly advance clinical practice. However, the integration of these data is non-trivial. Therefore, we will develop methods to analyze such cohort-derived molecular and clinical information and apply them in the context of drug-based precision oncology.